PL3512495T3 - Preparaty analogu prostacykliny - Google Patents
Preparaty analogu prostacyklinyInfo
- Publication number
- PL3512495T3 PL3512495T3 PL17768124.4T PL17768124T PL3512495T3 PL 3512495 T3 PL3512495 T3 PL 3512495T3 PL 17768124 T PL17768124 T PL 17768124T PL 3512495 T3 PL3512495 T3 PL 3512495T3
- Authority
- PL
- Poland
- Prior art keywords
- prostacyclin analogue
- analogue formulations
- formulations
- prostacyclin
- analogue
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/5578—Eicosanoids, e.g. leukotrienes or prostaglandins having a pentalene ring system, e.g. carbacyclin, iloprost
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/558—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
- A61K31/5585—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes having five-membered rings containing oxygen as the only ring hetero atom, e.g. prostacyclin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1274—Non-vesicle bilayer structures, e.g. liquid crystals, tubules, cubic phases or cochleates; Sponge phases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Dermatology (AREA)
- Vascular Medicine (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Dispersion Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1615754.7A GB201615754D0 (en) | 2016-09-15 | 2016-09-15 | Formulations |
| GBGB1621277.1A GB201621277D0 (en) | 2016-12-14 | 2016-12-14 | Formulations |
| PCT/EP2017/073359 WO2018050864A1 (en) | 2016-09-15 | 2017-09-15 | Prostacyclin analogue formulations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3512495T3 true PL3512495T3 (pl) | 2023-01-23 |
Family
ID=59887281
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL17768124.4T PL3512495T3 (pl) | 2016-09-15 | 2017-09-15 | Preparaty analogu prostacykliny |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US11369617B2 (pl) |
| EP (1) | EP3512495B1 (pl) |
| JP (1) | JP7527785B2 (pl) |
| KR (1) | KR20190083645A (pl) |
| CN (1) | CN109715138B (pl) |
| AU (1) | AU2017328630B2 (pl) |
| CA (1) | CA3036307A1 (pl) |
| DK (1) | DK3512495T3 (pl) |
| ES (1) | ES2933175T3 (pl) |
| IL (1) | IL265270B (pl) |
| LT (1) | LT3512495T (pl) |
| MX (1) | MX390136B (pl) |
| PL (1) | PL3512495T3 (pl) |
| PT (1) | PT3512495T (pl) |
| RU (1) | RU2757903C2 (pl) |
| SI (1) | SI3512495T1 (pl) |
| WO (1) | WO2018050864A1 (pl) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109150387B (zh) | 2017-06-16 | 2023-04-28 | 华为技术有限公司 | 发送参考信号的方法、接收参考信号的方法和通信装置 |
| WO2020240018A1 (en) | 2019-05-29 | 2020-12-03 | Camurus Ab | Administration device & regime |
| US20230248801A1 (en) * | 2020-06-30 | 2023-08-10 | Chong Kun Dang Pharmaceutical Corp. | INJECTABLE COMPOSITION COMPRISING GnRH ANALOGUE |
| JP2023543037A (ja) * | 2020-09-25 | 2023-10-12 | アルゴリズム サイエンシズ，インコーポレイテッド | 血管拡張剤送達のための組成物及び方法 |
| WO2024107096A1 (en) * | 2022-11-14 | 2024-05-23 | Camurus Ab | Treprostinil formulations |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4125255A1 (de) | 1991-07-31 | 1993-02-04 | Knoll Ag | Prostaglandin e (pfeil abwaerts)1(pfeil abwaerts)-formulierung |
| DE69425750T2 (de) | 1993-07-28 | 2001-04-26 | Pharmaderm Laboratories Ltd., Saskatoon | Zweiphasige multilamellare lipidvesikel |
| SE0201659D0 (sv) | 2002-05-31 | 2002-05-31 | Astrazeneca Ab | Modified release pharmaceutical formulation |
| CN101265226B (zh) * | 2003-05-22 | 2013-04-24 | 联合治疗公司 | 化合物和释放前列环素类似物的方法 |
| PL1768650T3 (pl) * | 2004-06-04 | 2009-01-30 | Camurus Ab | Ciekłe formulacje depot |
| GB0412530D0 (en) * | 2004-06-04 | 2004-07-07 | Camurus Ab | Formulation |
| US20060147520A1 (en) * | 2004-07-26 | 2006-07-06 | Curtis Ruegg | Treatment of pulmonary hypertension by inhaled iloprost with a microparticle formulation |
| WO2006075125A1 (en) | 2005-01-14 | 2006-07-20 | Camurus Ab | GnRH ANALOGUE FORMULATIONS |
| CA2609810C (en) | 2005-06-06 | 2012-05-22 | Camurus Ab | Glp-1 analogue formulations |
| EP2714004B1 (en) | 2011-05-25 | 2024-05-15 | Camurus AB | Controlled release peptide formulations |
| BR112014003240A2 (pt) | 2011-08-12 | 2017-03-01 | Ascendis Pharma As | composição de prostaciclina com liberação sustentada |
| JP6092867B2 (ja) * | 2011-08-12 | 2017-03-08 | アセンディス ファーマ エー／エス | 担体連結しているトレプロスチニルプロドラッグ |
| WO2013038460A1 (ja) | 2011-09-16 | 2013-03-21 | 株式会社日立製作所 | 画像表示システム及びその方法 |
| DK2787974T3 (en) * | 2011-12-05 | 2017-07-17 | Camurus Ab | Robust PEPTID FORMULATIONS WITH CONTROLLED RELEASE |
| AU2013294915C1 (en) * | 2012-07-26 | 2019-11-21 | Camurus Ab | Opioid formulations |
| JP6357481B2 (ja) | 2012-11-30 | 2018-07-11 | インスメッド， インコーポレイテッド | プロスタサイクリン化合物およびプロスタサイクリン化合物を使用する方法 |
| KR101586790B1 (ko) | 2012-12-28 | 2016-01-19 | 주식회사 종근당 | 음이온성 약리학적 활성물질의 서방성 지질 초기제제 및 이를 포함하는 약제학적 조성물 |
| WO2015138423A1 (en) | 2014-03-11 | 2015-09-17 | Insmed Incorporated | Prostacylin compositions and methods for using the same |
| GB201419091D0 (en) | 2014-10-27 | 2014-12-10 | Camurus Ab | Formulations |
| US9394227B1 (en) | 2015-06-17 | 2016-07-19 | Corsair Pharma, Inc. | Treprostinil derivatives and compositions and uses thereof |
-
2017
- 2017-09-15 EP EP17768124.4A patent/EP3512495B1/en active Active
- 2017-09-15 ES ES17768124T patent/ES2933175T3/es active Active
- 2017-09-15 IL IL265270A patent/IL265270B/en unknown
- 2017-09-15 CA CA3036307A patent/CA3036307A1/en active Pending
- 2017-09-15 AU AU2017328630A patent/AU2017328630B2/en active Active
- 2017-09-15 PT PT177681244T patent/PT3512495T/pt unknown
- 2017-09-15 SI SI201731280T patent/SI3512495T1/sl unknown
- 2017-09-15 JP JP2019514208A patent/JP7527785B2/ja active Active
- 2017-09-15 CN CN201780056712.7A patent/CN109715138B/zh active Active
- 2017-09-15 RU RU2019108832A patent/RU2757903C2/ru active
- 2017-09-15 US US16/333,448 patent/US11369617B2/en active Active
- 2017-09-15 MX MX2019002999A patent/MX390136B/es unknown
- 2017-09-15 LT LTEPPCT/EP2017/073359T patent/LT3512495T/lt unknown
- 2017-09-15 PL PL17768124.4T patent/PL3512495T3/pl unknown
- 2017-09-15 DK DK17768124.4T patent/DK3512495T3/da active
- 2017-09-15 KR KR1020197008219A patent/KR20190083645A/ko not_active Ceased
- 2017-09-15 WO PCT/EP2017/073359 patent/WO2018050864A1/en not_active Ceased
-
2022
- 2022-06-09 US US17/836,120 patent/US20220387445A1/en not_active Abandoned
-
2024
- 2024-11-12 US US18/945,113 patent/US20250319097A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2019529408A (ja) | 2019-10-17 |
| US20190255068A1 (en) | 2019-08-22 |
| CA3036307A1 (en) | 2018-03-22 |
| EP3512495B1 (en) | 2022-11-09 |
| KR20190083645A (ko) | 2019-07-12 |
| CN109715138B (zh) | 2022-06-28 |
| JP7527785B2 (ja) | 2024-08-05 |
| US11369617B2 (en) | 2022-06-28 |
| MX390136B (es) | 2025-03-20 |
| ES2933175T3 (es) | 2023-02-02 |
| US20220387445A1 (en) | 2022-12-08 |
| MX2019002999A (es) | 2019-07-18 |
| EP3512495A1 (en) | 2019-07-24 |
| RU2757903C2 (ru) | 2021-10-22 |
| AU2017328630A1 (en) | 2019-04-11 |
| AU2017328630B2 (en) | 2020-06-18 |
| RU2019108832A (ru) | 2020-10-15 |
| SI3512495T1 (sl) | 2023-01-31 |
| IL265270B (en) | 2022-09-01 |
| PT3512495T (pt) | 2023-02-15 |
| LT3512495T (lt) | 2022-12-27 |
| RU2019108832A3 (pl) | 2020-11-30 |
| US20250319097A1 (en) | 2025-10-16 |
| IL265270A (en) | 2019-05-30 |
| DK3512495T3 (da) | 2022-12-05 |
| CN109715138A (zh) | 2019-05-03 |
| WO2018050864A1 (en) | 2018-03-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL273541A (en) | formulations | |
| IL273282A (en) | Niraprib formulations | |
| IL269630A (en) | Niraprib formulations | |
| IL269621A (en) | Niraparib formulations | |
| IL265609A (en) | New formulations | |
| GB201607918D0 (en) | Novel formulations | |
| PL3474822T3 (pl) | Preparaty brincydofowiru | |
| GB201707189D0 (en) | Novel formulations | |
| IL265270A (en) | Prostacyclin analog formulations | |
| GB201809976D0 (en) | Novel formulations | |
| IL272857A (en) | Cofanalisib formulations | |
| GB201707188D0 (en) | Novel formulations | |
| GB201707187D0 (en) | Novel formulations | |
| PT3678644T (pt) | Formulações de copanlisib | |
| IL254075B (en) | Resistant preparations to repel pests | |
| IL268195A (en) | Solid fosmetpantothenate formulations | |
| SG11202011823SA (en) | Activator-nucleator formulations | |
| GB201819028D0 (en) | Butanol-based formulations | |
| GB201714461D0 (en) | Formulations | |
| GB201716291D0 (en) | Novel formulations | |
| GB201808386D0 (en) | Formulations | |
| GB201707562D0 (en) | Novel formulations | |
| GB201707564D0 (en) | Novel formulations | |
| GB201707190D0 (en) | Novel Formulations | |
| GB201804545D0 (en) | Formulations |